focus -WSS

focus

author：hotspot 2025-10-02 09:38:17 Page View：56

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： National associations that represent hospice owe an apology
Next article： Tori Bowie and the unacceptable rates of Black maternal death

explore

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

FDA greenlights medical device to combat bladder issues

AndrewHarnik/APYou’rereadingthewebeditionofSTATHealthTech,ourguidetohowtechistransformingthelifescie

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Healthy food access boosts outcomes in two studies

HealthyFoodRx'slivestreamofacookingclassduringmealprep.DanSocie/AbbotFundInStockton,California,almos